EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study

Ding Peng iD, Huihong Zhai iD

Therapeutic Advances in Gastroenterology · 2025-07 · 18

DOI: 10.1177/17562848251342864 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 09.06.2025. Verfasst von Ding Peng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xuanwu Hospital Capital Medical University, Changchun Street 45#, 100053 Beijing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal bleeding (GIB) is a critical clinical emergency associated with high morbidity and mortality. The widespread use of antithrombotic agents, including antiplatelet and anticoagulant medications, has increased the incidence of GIB.

Objectives

Our study aims to address this gap by evaluating the impact of antithrombotic therapy on both 28-day mortality and rebleeding risk.

Design

Retrospective cohort study using propensity score-based methods to address confounding.

Methods

Data were extracted from three independent databases (MIMIC-IV, NWICU, and Xuanwu Hospital) spanning 2008–2022. inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. Weighted logistic regression models assessed outcomes across antiplatelet, anticoagulant, and combination therapy subgroups.

Results

After inverse probability of treatment weighting (IPTW) adjustment, the antithrombotic group maintained a significantly elevated rebleeding rate (19.9% vs 10.5%, p < 0.001) and an increased risk of rebleeding (odds ratio (OR) = 2.118, 95% confidence interval (CI): 1.577–2.845, p < 0.001). Conversely, the 28-day mortality was significantly lower in the antithrombotic group postadjustment (8.2% vs 12.5%, p = 0.022; OR = 0.621, 95% CI: 0.412–0.935, p = 0.023). Notably, early resumption of antithrombotic therapy (within 3 days) significantly increased the risk of mortality.

Conclusion

Our study suggests that while antithrombotic therapy reduces 28-day mortality, it significantly increases rebleeding risk. Notably, the use of anticoagulants or combination therapy is linked to the highest rebleeding risk, compared to antiplatelets. Additionally, resuming antithrombotic therapy too early (i.e., within 3 days) may further elevate the risk of mortality.

Schlagwörter

Stichwörter der Autor:innen

28-day mortalityantithrombotic therapygastrointestinal bleedingrebleeding risk

Autor:innen und Institutionen

  • Department of Gastroenterology, Xuanwu Hospital Capital Medical University, Changchun Street 45#, 100053 Beijing, China.

ORCID-Profile: Ding Peng, Huihong Zhai

Zitieren

APA

Peng, D., & Zhai, H. (2025). Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study. Therapeutic Advances in Gastroenterology, 18. https://doi.org/10.1177/17562848251342864

Vancouver

Peng D, Zhai H. Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study. Therapeutic Advances in Gastroenterology. 2025;18. doi:10.1177/17562848251342864

BibTeX
@article{Peng2025,
  author = {Peng, Ding and Zhai, Huihong},
  title = {Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study},
  journal = {Therapeutic Advances in Gastroenterology},
  year = {2025},
  volume = {18},
  doi = {10.1177/17562848251342864}
}
Kostenlos starten →